- Home
- ITIC vs BDTX Comparison
ITIC vs BDTX Comparison
Compare ITIC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | BDTX |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.6M | 171.9M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITIC | BDTX |
|---|---|---|
| Price | $284.60 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 46.3K | ★ 510.7K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | 13.02 | ★ 130.71 |
| EPS | ★ 10.93 | N/A |
| Revenue | ★ $272,755,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.28 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $209.75 | $1.60 |
| 52 Week High | $309.55 | $4.94 |
Technical Indicators
Market Signals| Indicator | ITIC | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 37.69 |
| Support Level | $275.52 | $1.76 |
| Resistance Level | $294.88 | $1.90 |
| Average True Range (ATR) | 7.38 | 0.09 |
| MACD | -1.78 | -0.02 |
| Stochastic Oscillator | 20.52 | 7.83 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.